ClinicalTrials.gg
Active, not recruitingNCT06280209Updated Jun 25, 2026

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy

A Phase 1/2 interventional study of BMN 351 in Duchenne Muscular Dystrophy, sponsored by BioMarin Pharmaceutical. Active, not recruiting at 7 sites in 5 countries. Open to male participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by BioMarin Pharmaceutical · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
4 Years to 10 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Muscular Dystrophy, Duchenne by BioMarin Pharmaceutical — 1 open to participants now, 2 under way, none of them phase 3. Muscular Dystrophy, Duchenne · BioMarin Pharmaceutical.

Started
2024
the only one that year
Phase 1/2
4 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Muscular Dystrophy, Duchenne by BioMarin Pharmaceutical, this one is the only one that started in 2024, is one of 4 in phase 1/2, and was the 9th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

1 of the 10 studies in Muscular Dystrophy, Duchenne by BioMarin Pharmaceutical is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 10 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Muscular Dystrophy, Duchenne by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and tolerability of BMN 351 in participants with Duchenne Muscular Dystrophy (DMD) with a genetic mutation amenable to exon 51 skipping.

Read the detailed description

This is Phase 1/2, open-label, multi-center study consisting of 2 parts to evaluate the safety and tolerability of BMN 351 at escalating doses in participants with Duchenne Muscular Dystrophy (DMD) with genetic mutations amenable to exon 51 skipping.

Participants will be assigned to one of three groups called cohorts (Cohort 1, 2 or 3). Cohort 1 participants are further divided into Cohort 1A and Cohort 1B. In Cohort 1A, 3 participants will receive increasing doses once every 2 weeks with a visit to assess safety measures collected the week after dosing prior to escalating doses of BMN 351. In part 2, the participants in cohort 1A will transition to once weekly dosing. The participants in Cohort 1B, 2, and 3 will initiate low, medium, and high doses of BMN 351 and continue once weekly dosing at that same dose. The study will enroll approximately 18 participants.

03

Conditions studied

  • Duchenne Muscular Dystrophy
04

Who can participate

Ages eligible
4 Years to 10 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 4 to 10
  • Diagnosis of Duchenne muscular dystrophy with a specific genetic change amenable to exon 51 skipping
  • Able to walk
  • Not requiring assistance from a ventilator to breathe
  • Currently on consistent doses of treatment for the last 12 weeks

Exclusion criteria

Exclusion Criteria:

  • The participant will have some initial clinical labs and studies to assess baseline level of heart and lung function.
  • Treatment with an exon skipping therapy within 12 weeks prior to the first visit.
  • Any history of treatment with gene therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort 1A

    Cohort 1A will consist of both a single ascending dose (SAD) part and a multiple ascending dose (MAD). BMN 351 will be administered once every 2 weeks during the SAD portion of the study for up to 8 weeks and once weekly during the MAD portion for up to 89 weeks.

    Drug: BMN 351

  • Experimental
    Cohort 1B

    BMN 351 low dose will be administered once weekly for up to 97 weeks

    Drug: BMN 351

  • Experimental
    Cohort 2

    BMN 351 medium dose will be administered once weekly for up to 73 weeks

    Drug: BMN 351

  • Experimental
    Cohort 3

    BMN 351 high dose will be administered once weekly for up to 48 weeks

    Drug: BMN 351

Interventions

  • DrugBMN 351

    Anti-sense Oligonucleotide BMN 351 will be administered intravenously.

06

What researchers measure

Primary outcomes

  1. To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters).

    The safety and tolerability of BMN 351 will be assessed based on the incidence of adverse and serious adverse events.

    Time frame: Up to 97 weeks.

Secondary outcomes

  1. Pharmacokinetics (PK) concentration of BMN 351 in plasma, urine and muscle approximately every 8 weeks for up to 97 weeks.

    Serial measurements of plasma and urine PK predose approximately hourly up to 24 hours post-infusion. Muscle PK will be measured at 13 weeks or 25 weeks only post dosing.

    Time frame: Serial measurements pre and post infusion.

Other outcomes

  1. To evaluate the immune response to BMN 351.

    Anti-BMN 351 antibodies, anti-dystrophin antibodies.

    Time frame: Up to 97 weeks

  2. To evaluate the effect of BMN 351 on physical function.

    Change from baseline on 6 Minute Walk Test (6MWT).

    Time frame: Change from baseline at week 25.

  3. To evaluate the effect of BMN 351 on physical function.

    Change from baseline on North Star Ambulatory Assessment (NSAA).

    Time frame: Change from baseline at week 25.

  4. Change from baseline in dystrophin expression measured by Liquid chromatography-mass spectrometry (LC-MS).

    Time frame: Baseline, Week 13 or Week 25

07

Study locations

7 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Apr 2027, 39 months after the start.

Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 28, 2024
StartActual
Jan 3, 2024
Primary completionEst.
Apr 14, 2027
CompletionEst.
Apr 14, 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06280209
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Jan 3, 2024
Primary completion
Apr 14, 2027 (estimated)
Completion
Apr 14, 2027 (estimated)
Last update
Jun 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion